| Symbol | ROIV |
|---|---|
| Name | ROIVANT SCIENCES LTD. |
| Sector | HEALTH CARE |
| Region | Europe |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 11-12 ST. JAMESS SQUARE,SUITE 1, 3RD FLOOR, LONDON, SW1Y 4LB, United Kingdom |
| Telephone | +44 2074003347 |
| Fax | — |
| — | |
| Website | https://www.roivant.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001635088 |
| Description | Roivant Sciences Ltd is a biopharmaceutical company dedicated to improving the delivery of healthcare to patients. Additional info from NASDAQ: |
📋 MAYUKH SUKHATME (Officer) plans to sell 285K shares of ROIVANT SCIENCES LTD. (at $36.25 each, total $10.3M) Filed: Aug 17, 2026 | ID: 008265
Read moreNew Form SCHEDULE 13G/A - Roivant Sciences Ltd. <b>Filed:</b> 2026-08-13 <b>AccNo:</b> 0000895421-26-000250 <b>Size:</b> 12 KB
Read moreVenker Eric 🟡 adjusted position in 200.0K shares (1 derivative) of Roivant Sciences Ltd. (ROIV) at $34.95 ($8.5M) Transaction Date: Jul 27, 2026 | Filing ID: 030107
Read moreNew Form ARS - Roivant Sciences Ltd. <b>Filed:</b> 2026-07-29 <b>AccNo:</b> 0001140361-26-029957 <b>Size:</b> 5 MB
Read moreNew Form DEFA14A - Roivant Sciences Ltd. <b>Filed:</b> 2026-07-29 <b>AccNo:</b> 0001140361-26-029956 <b>Size:</b> 7 MB
Read moreNew Form DEF 14A - Roivant Sciences Ltd. <b>Filed:</b> 2026-07-29 <b>AccNo:</b> 0001140361-26-029955 <b>Size:</b> 7 MB
Read moreRoivant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026
Read moreMOMTAZEE JAMES C 🟢 acquired 405 shares of Roivant Sciences Ltd. (ROIV) Transaction Date: Jul 17, 2026 | Filing ID: 029193
Read moreEpperly Melissa B, 🟢 acquired 543 shares of Roivant Sciences Ltd. (ROIV) Transaction Date: Jul 17, 2026 | Filing ID: 029192
Read moreOren Ilan 🟢 acquired 775 shares of Roivant Sciences Ltd. (ROIV) Transaction Date: Jul 17, 2026 | Filing ID: 029191
Read more| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| RVT-101 | DRUG | Phase PHASE3 | Alzheimer's Disease | COMPLETED | NCT02585934 |
| RVT-101 70 mg | DRUG | Phase PHASE2 | Dementia With Lewy Bodies | TERMINATED | NCT02928445 |
| RVT-101 35 mg tablets | DRUG | Phase PHASE3 | Alzheimer's Disease | TERMINATED | NCT02586909 |
| RVT-101 35 mg | DRUG | Phase PHASE2 | Dementia With Lewy Bodies | TERMINATED | NCT02928445 |
| Placebo | DRUG | Phase PHASE2 | Lewy Body Dementia | COMPLETED | NCT02640729 |
| Nelotanserin | DRUG | Phase PHASE2 | Lewy Body Dementia | COMPLETED | NCT02640729 |